SVB Securities Keeps Their Buy Rating on Xeris Pharmaceuticals (XERS)

SVB Securities analyst Roanna Ruiz reiterated a Buy rating on Xeris Pharmaceuticals (XERSResearch Report) on September 7. The company’s shares closed last Friday at $1.82.

Ruiz covers the Healthcare sector, focusing on stocks such as Lantheus, Myovant Sciences, and scPharmaceuticals. According to TipRanks, Ruiz has an average return of -46.7% and a 15.79% success rate on recommended stocks.

Xeris Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

See the top stocks recommended by analysts >>

The company has a one-year high of $3.17 and a one-year low of $1.25. Currently, Xeris Pharmaceuticals has an average volume of 1.13M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xeris Pharmaceuticals, a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.

Read More on XERS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More